JÃ¼rgen C Becker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10653671/publications.pdf

Version: 2024-02-01

94	11,282	53751 45	39638 94
papers	citations	h-index	g-index

98	98	98	13810
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	S2kâ€Guidelines â€“ Cutaneous lymphomas (ICD10 C82 â€•C86): Update 2021. JDDG - Journal of the German Society of Dermatology, 2022, 20, 537-554.	0.4	8
2	S2kâ€Leitlinie â€“ Kutane Lymphome (ICD10 C82â€“C86): Update 2021. JDDG - Journal of the German Society of Dermatology, 2022, 20, 537-555.	0.4	10
3	The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells. Journal of Investigative Dermatology, 2021, 141, 903-912.e4.	0.3	31
4	Mutational Landscape of Virus- and UV-Associated Merkel Cell Carcinoma Cell Lines Is Comparable to Tumor Tissue. Cancers, 2021, 13, 649.	1.7	16
5	Classical and Variant Merkel Cell Carcinoma Cell Lines Display Different Degrees of Neuroendocrine Differentiation and Epithelial-Mesenchymal Transition. Journal of Investigative Dermatology, 2021, 141, 1675-1686.e4.	0.3	13
6	High-resolution analysis of Merkel Cell Polyomavirus in Merkel Cell Carcinoma reveals distinct integration patterns and suggests NHEJ and MMBIR as underlying mechanisms. PLoS Pathogens, 2020, 16, e1008562.	2.1	24
7	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. European Journal of Cancer, 2020, 130, 126-138.	1.3	84
8	Artesunate Affects T Antigen Expression and Survival of Virus-Positive Merkel Cell Carcinoma. Cancers, 2020, 12, 919.	1.7	17
9	S2kâ€Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) â€“ Update 2018. JDDG - Journal of the German Society of Dermatology, 2019, 17, 562-577.	0.4	13
10	S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) â€“ update 2018. JDDG - Journal of the German Society of Dermatology, 2019, 17, 562-576.	0.4	27
11	Characterization of six Merkel cell polyomavirusâ€positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration. International Journal of Cancer, 2019, 145, 1020-1032.	2.3	44
12	Conversion of Sox2-dependent Merkel cell carcinoma to a differentiated neuron-like phenotype by T antigen inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20104-20114.	3.3	41
13	A shortâ€term in vivo model for Merkel Cell Carcinoma. Experimental Dermatology, 2018, 27, 684-687.	1.4	8
14	S2kâ€Leitlinie â€“ Kutane Lymphome Update 2016 â€“ Teil 2: Therapie und Nachsorge (ICD10 C82 â€•C86). JDDG - Journal of the German Society of Dermatology, 2018, 16, 112-123.	0.4	14
15	S2k Guidelines â€“ Cutaneous Lymphomas Update 2016 â€“ Part 2: Treatment and Followâ€up (ICD10 C82 â€•C86). JDDG - Journal of the German Society of Dermatology, 2018, 16, 112-122.	0.4	29
16	Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leukemia and Lymphoma, 2018, 59, 880-887.	0.6	28
17	Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. Cancer Immunology, Immunotherapy, 2018, 67, 341-351.	2.0	88
18	Genomic Landscape of Spitzoid Neoplasms Impacting Patient Management. Frontiers in Medicine, 2018, 5, 344.	1.2	18

#	Article	IF	Citations
19	T cell receptor repertoire usage in cancer as a surrogate marker for immune responses. Seminars in Immunopathology, 2017, 39, 255-268.	2.8	65
20	Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. European Journal of Cancer, 2017, 71, 53-69.	1.3	307
21	Merkel cell carcinoma. Nature Reviews Disease Primers, 2017, 3, 17077.	18.1	393
22	Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. Scientific Reports, 2016, 6, 21678.	1.6	43
23	Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution. Cell Metabolism, 2016, 23, 554-562.	7.2	572
24	Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 2847-2854.	0.6	17
25	Presence of Human Polyomavirus 6 in Mutation-Specific BRAF Inhibitorâ€“Induced Epithelial Proliferations. JAMA Dermatology, 2014, 150, 1180.	2.0	51
26	Fluorescencein situhybridization and qPCR to detect Merkel cell polyomavirus physical status and load in Merkel cell carcinomas. International Journal of Cancer, 2014, 135, 2804-2815.	2.3	13
27	T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors. Clinical Cancer Research, 2014, 20, 1768-1778.	3.2	81
28	Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma. Cancer Immunology Research, 2014, 2, 1071-1079.	1.6	120
29	p53 Regulation by TRP2 Is Not Pervasive in Melanoma. PLoS ONE, 2014, 9, e87440.	1.1	2
30	Immune-suppressive properties of the tumor microenvironment. Cancer Immunology, Immunotherapy, 2013, 62, 1137-1148.	2.0	179
31	Survivin downregulation is not required for T antigen knockdown mediated cell growth inhibition in MCV infected merkel cell carcinoma cells. International Journal of Cancer, 2013, 132, 2980-2982.	2.3	7
32	Panobinostat activity in both bexarotene-exposed and -naÃ¯ve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. European Journal of Cancer, 2013, 49, 386-394.	1.3	124
33	Merkel Cell Polyomavirusâ€“Positive Merkel Cell Carcinoma Cells Do Not Require Expression of the Viral Small T Antigen. Journal of Investigative Dermatology, 2013, 133, 2059-2064.	0.3	41
34	No Evidence for Association of HPyV6 or HPyV7 with Different Skin Cancers. Journal of Investigative Dermatology, 2012, 132, 239-241.	0.3	22
35	Control of Central and Peripheral Tolerance to Melanocyte Differentiation Antigens by GILT. Journal of Investigative Dermatology, 2012, 132, 15-17.	0.3	3
36	Type I and II IFNs Inhibit Merkel Cell Carcinoma via Modulation of the Merkel Cell Polyomavirus T Antigens. Cancer Research, 2012, 72, 2120-2128.	0.4	49

#	Article	IF	Citations
37	Merkel Cell Carcinoma and Merkel Cell Polyomavirus: Evidence for Hit-and-Run Oncogenesis. Journal of Investigative Dermatology, 2012, 132, 254-256.	0.3	53
38	Merkel cell carcinoma. Current Opinion in Oncology, 2012, 24, 141-149.	1.1	95
39	Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012. Journal of Clinical Oncology, 2012, 30, 4091-4097.	0.8	94
40	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 107-114.	13.9	1,976
41	An intact retinoblastoma proteinâ€binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. International Journal of Cancer, 2012, 130, 847-856.	2.3	179
42	Merkel Cell Polyomavirus. , 2012, , 449-462.		0
43	Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genetics, 2011, 43, 1018-1021.	9.4	662
44	Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2011, 131, 1631-1638.	0.3	153
45	New Virus Associated With Merkel Cell Carcinoma Development. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 874-880.	2.3	45
46	The Etiology and Epidemiology of Merkel Cell Carcinoma. Current Problems in Cancer, 2010, 34, 14-37.	1.0	151
47	Mouse models for melanoma: a personal perspective. Experimental Dermatology, 2010, 19, 157-164.	1.4	71
48	Merkel Cell Polyomavirus-Infected Merkel Cell Carcinoma Cells Require Expression of Viral T Antigens. Journal of Virology, 2010, 84, 7064-7072.	1.5	386
49	Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology, 2010, 28, 4485-4491.	0.8	604
50	Quantitation of Human Seroresponsiveness to Merkel Cell Polyomavirus. PLoS Pathogens, 2009, 5, e1000578.	2.1	217
51	Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. International Journal of Cancer, 2009, 125, 1250-1256.	2.3	297
52	Identification and characterization of survivinâ€derived Hâ€2K^bâ€restricted CTL epitopes. European Journal of Immunology, 2009, 39, 1419-1424.	1.6	18
53	MC Polyomavirus Is Frequently Present in Merkel Cell Carcinoma of European Patients. Journal of Investigative Dermatology, 2009, 129, 248-250.	0.3	307
54	Proliferation Arrest in B-Raf Mutant Melanoma Cell Lines upon MAPK Pathway Activation. Journal of Investigative Dermatology, 2009, 129, 406-414.	0.3	18

#	Article	IF	Citations
55	Melanoma Inhibitor of Apoptosis Protein (ML-IAP) Specific Cytotoxic T Lymphocytes Cross-React with an Epitope from the Auto-Antigen SS56. Journal of Investigative Dermatology, 2009, 129, 1992-1999.	0.3	6
56	Molecular pathogenesis of Merkel cell carcinoma. Experimental Dermatology, 2009, 18, 193-198.	1.4	87
57	Immunological tumor destruction in a murine melanoma model by targeted LTÎ± independent of secondary lymphoid tissue. Cancer Immunology, Immunotherapy, 2008, 57, 85-95.	2.0	54
58	Anti-cancer therapies targeting the tumor stroma. Cancer Immunology, Immunotherapy, 2008, 57, 1-17.	2.0	137
59	Cancer treatment: the combination of vaccination with other therapies. Cancer Immunology, Immunotherapy, 2008, 57, 1735-1743.	2.0	48
60	Merkel cell carcinoma: molecular pathogenesis, clinical features and therapy. JDDG - Journal of the German Society of Dermatology, 2008, 6, 709-719.	0.4	70
61	BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC. Journal of Carcinogenesis, 2008, 7, 1.	2.5	17
62	B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis. PLoS ONE, 2007, 2, e236.	1.1	133
63	Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. Journal of Cancer Research and Clinical Oncology, 2007, 133, 897-901.	1.2	21
64	Antibody targeted drugs as cancer therapeutics. Nature Reviews Drug Discovery, 2006, 5, 147-159.	21.5	677
65	Cytotoxic T Cells. Journal of Investigative Dermatology, 2006, 126, 32-41.	0.3	316
66	Tumor stroma-associated antigens for anti-cancer immunotherapy. Cancer Immunology, Immunotherapy, 2006, 55, 481-494.	2.0	42
67	Therapeutic efficacy of tumor-targeted IL2 in LTÎ±â^'/â^' mice depends on conditioned T cells. Cancer Immunology, Immunotherapy, 2006, 55, 861-866.	2.0	6
68	Molecularly targeted therapy for melanoma. Cancer, 2006, 107, 2317-2327.	2.0	50
69	Regulators of apoptosis: suitable targets for immune therapy of cancer. Nature Reviews Drug Discovery, 2005, 4, 399-409.	21.5	97
70	Absence of mutations in the coding sequence of the potential tumor suppressor 3pK in metastatic melanoma. Journal of Carcinogenesis, 2005, 4, 23.	2.5	3
71	Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine, 2005, 23, 884-889.	1.7	105
72	Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. Journal of Carcinogenesis, 2004, 3, 6.	2.5	258

#	Article	IF	Citations
73	Shift from Systemic to Site-Specific Memory by Tumor-Targeted IL-2. Journal of Immunology, 2004, 172, 5843-5850.	0.4	16
74	Immunogenicity of Constitutively Active V599EBRaf. Cancer Research, 2004, 64, 5456-5460.	0.4	71
75	B-Raf specific antibody responses in melanoma patients. BMC Cancer, 2004, 4, 62.	1.1	21
76	Hypopigmentary Skin Disorders. Drugs, 2004, 64, 89-107.	4.9	37
77	Immunological consequences of the sentinel lymph-node biopsyâ€"lessons from a melanoma patient. Lancet Oncology, The, 2003, 4, 446-447.	5.1	5
78	A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature Medicine, 2002, 8, 1369-1375.	15.2	359
79	Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. European Journal of Immunology, 2002, 32, 122-127.	1.6	38
80	Differential Expression of Inhibitory or Activating CD94/NKG2 Subtypes on MART-1-Reactive T Cells in Vitiligo Versus Melanoma: A Case Report. Journal of Investigative Dermatology, 2002, 118, 595-599.	0.3	16
81	Aggregation of Antigen-Specific T Cells at the Inoculation Site of Mature Dendritic Cells. Journal of Investigative Dermatology, 2002, 119, 1443-1448.	0.3	30
82	Identical T-cell receptor transcripts in multiple melanoma metastases. Cancer Research, 2002, 62, 5664-7.	0.4	6
83	Targeting of Lymphotoxin-Î± to the Tumor Elicits an Efficient Immune Response Associated with Induction of Peripheral Lymphoid-like Tissue. Immunity, 2001, 14, 111-121.	6.6	170
84	Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression. International Journal of Cancer, 2001, 94, 820-824.	2.3	42
85	In situ cytokine therapy: redistribution of clonally expanded T cells. European Journal of Immunology, 2001, 31, 250-258.	1.6	18
86	Differential expression of CD28 and CD94 / NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node. European Journal of Immunology, 2000, 30, 3699-3706.	1.6	27
87	Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Therapy, 2000, 7, 316-323.	2.2	65
88	Comparative delineation of T cell clonotypes in coexisting syngeneic B16 melanoma. Cancer Immunology, Immunotherapy, 2000, 49, 426-432.	2.0	7
89	Accumulation of Identical T Cells in Melanoma and Vitiligo-Like Leukoderma. Journal of Investigative Dermatology, 1999, 113, 1033-1038.	0.3	70
90	Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunology, Immunotherapy, 1996, 42, 88-92.	2.0	39

#	Article	IF	Citations
91	Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer, 1995, 75, 2784-2785.	2.0	46
92	Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer, 1994, 73, 1621-1624.	2.0	81
93	A member of the melanoma antigen-encoding gene (MAGE) family is expressed in human skin during wound healing. International Journal of Cancer, 1994, 58, 346-348.	2.3	47
94	Prevention of anergy induction in cloned T cells by interleukin 12. Experimental Dermatology, 1994, 3, 283-289.	1.4	7